New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease

BioArctic’s partner Eisai presented new AAIC 2026 (London, July 12-15) data showing Leqembi (lecanemab) in a subcutaneous formulation. The article does not provide effect-size results or safety metrics in the provided excerpt, so the immediate implications are unclear. Overall this reads as routine clinical-update/newsflow rather than a confirmed earnings/approval catalyst.

Analysis

BioArctic’s partner Eisai presented new AAIC 2026 (London, July 12-15) data showing Leqembi (lecanemab) in a subcutaneous formulation. The article does not provide effect-size results or safety metrics in the provided excerpt, so the immediate implications are unclear. Overall this reads as routine clinical-update/newsflow rather than a confirmed earnings/approval catalyst.